Sage Therapeutics (NASDAQ:SAGE) Cut to "Sell" at StockNews.com

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Friday.

SAGE has been the topic of several other research reports. Royal Bank of Canada increased their price target on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 15th. Oppenheimer dropped their price target on shares of Sage Therapeutics from $25.00 to $17.00 and set a "market perform" rating on the stock in a research note on Thursday. HC Wainwright reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Wedbush reaffirmed a "neutral" rating and set a $24.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a report on Thursday. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $39.28.

Sage Therapeutics Stock Up 2.3 %

Shares of SAGE traded up $0.29 during mid-day trading on Friday, hitting $13.33. 1,258,722 shares of the company's stock were exchanged, compared to its average volume of 1,009,849. The firm has a fifty day moving average of $19.85 and a two-hundred day moving average of $20.91. Sage Therapeutics has a twelve month low of $10.92 and a twelve month high of $59.99. The stock has a market cap of $801.27 million, a price-to-earnings ratio of -1.47 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. During the same quarter in the prior year, the business posted ($2.47) EPS. Sage Therapeutics's quarterly revenue was up 2621.5% on a year-over-year basis. On average, equities analysts predict that Sage Therapeutics will post -6.06 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds have recently made changes to their positions in SAGE. CWM LLC increased its position in Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 883 shares in the last quarter. KBC Group NV acquired a new stake in Sage Therapeutics in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. increased its position in Sage Therapeutics by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 748 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Sage Therapeutics in the 1st quarter valued at about $34,000. Finally, Tower Research Capital LLC TRC increased its position in Sage Therapeutics by 74.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 2,148 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.